Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication.

Journal of clinical psychopharmacology - 1 Dec 2010

Gregoor Jochem G, Mulder Hans, Cohen Dan, van Megen Harold J G M, Egberts Toine C G, Heerdink Eibert R, van der Weide Jan

Abstract excerpt

Obesity is one of the most serious common somatic adverse effects of atypical antipsychotic agents. Genetic factors partly determine the individual patients risk of developing obesity during treatment. As weight-regulating mechanisms, such as the leptinergic and serotonergic system, may be interdependent, genetic polymorphisms in these systems also may show interactions. To determine whether combined HTR2CLEP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Body Mass Index

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Leptin

Share to Obesity

Share to Psychotic Disorders

Share to Receptor, Serotonin, 5-HT2C

Share to Receptors, Leptin

Source

Identifiers

PMID: 21105285
DOI: 10.1097/jcp.0b013e3181fa05a2

Genes

LEP
LEPR

Variants

rs1414334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication.PMID 21105285Read ↗

Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.Semantic proximity Read ↗

Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting.Semantic proximity Read ↗

The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study.Semantic proximity Read ↗

Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain.Semantic proximity Read ↗

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia.Semantic proximity Read ↗

Pharmacogenetics of Leptin in Antipsychotic-Associated Weight Gain and Obesity-Related ComplicationsSemantic proximity Read ↗

Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs.Semantic proximity Read ↗

Genetics of antipsychotic-induced weight gain: update and current perspectives.Semantic proximity Read ↗

Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment.Semantic proximity Read ↗

Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia.Semantic proximity Read ↗

Association Between HTR2C and HTR2A Polymorphisms and Metabolic Abnormalities in Patients Treated With Olanzapine or ClozapineSemantic proximity Read ↗

Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.